Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
| Member | Definition | Class |
|---|
| (R)-fluoxetine | An N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine that has R configuration. [The antidepressant drug fluoxetine is a racemate comprising equimolar amounts of (R)- and (S)-fluoxetine]. | (R)-fluoxetine |
| (R)-fluoxetine hydrochloride | A hydrochloride obtained by reaction of (R)-fluoxetine with one equivalent of hydrochloric acid. | (R)-fluoxetine hydrochloride |
| (S)-fluoxetine hydrochloride | A hydrochloride obtained by reaction of (S)-fluoxetine with one equivalent of hydrochloric acid. | (S)-fluoxetine hydrochloride |
| 7,8-dihydroxyflavone | A dihydroxyflavone that is flavone substituted by hydroxy groups at positions 7 and 8. A dihydroxyflavone that is flavone substituted by hydroxy groups at positions 7 and 8. A naturally occurring flavonoid produced by several plants, including the weed Tridax procumbens (coalbuttons or tridax daisy) and the tree Godmania aesculifolia, In animal models, it has shown efficacy against several diseases of the nervous system, including Alzheimer's, Parkinson's, and Huntington's. | 7,8-dihydroxyflavone |
| 8-bromo cyclic adenosine monophosphate | A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic AMP bearing an additional bromo substituent at position 8 on the adenine ring. An activator of cyclic AMP-dependent protein kinase, but resistant to degradation by cyclic AMP phosphodiesterase. | 8-Br-cAMP |
| adinazolam | A triazolo[4,3-a][1,4]benzodiazepine having a dimethylaminomethyl group at the 1-position, a phenyl group at the 6-position and a chloro substituent at the 8-position. | adinazolam |
| am 251 | A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor. | AM-251 |
| amineptin | A carbocyclic fatty acid that is 5-aminoheptanoic acid in which one of the hydrogens attached to the nitrogen is replaced by a 10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl group. A tricyclic antidepressant, it was never approved in the US and was withdrawn from the French market in 1999 due to concerns over abuse, dependence and severe acne. | amineptine |
| amitriptyline | An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5. | amitriptyline |
| amoxapine | A dibenzooxazepine compound having a chloro substituent at the 2-position and a piperazin-1-yl group at the 11-position. | amoxapine |
| ANA-12 | A secondary carboxamide that is anthranilic acid in which the carboxy group has undergone condensation with the primary amino group of alpha-amino-epsilon-caprolactam, while the aryl-amino group has undergone condensation with the carboxy group of 1-benzothiophene-2-carboxylic acid. It is a selective, non-competitive antagonist of tropomyosin receptor kinase B (TrkB, also known as tyrosine receptor kinase B). | ANA-12 |
| aprepitant | A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. | aprepitant |
| atomoxetine | A secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents. | atomoxetine |
| atomoxetine hydrochloride | The hydrochloride salt of atomoxetine. | atomoxetine hydrochloride |
| brexanolone | A 3-hydroxy-5alpha-pregnan-20-one in which the hydroxy group at position 3 has alpha-configuration. It is a metabolite of the sex hormone progesterone and used for the treatment of postpartum depression in women. | brexanolone |
| bupropion | An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring. | bupropion |
| chlorpheniramine | A tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma. | chlorphenamine |
| clomipramine | A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias. | clomipramine |
| clomipramine hydrochloride | A hydrochloride resulting from the reaction of equimolar amounts of clomipramine and hydrogen chloride. One of the more sedating tricyclic antidepressants, it is used for the treatment of depression as well as obsessive-compulsive disorder and phobias. | clomipramine hydrochloride |
| clorgyline | An aromatic ether that is the 2,4-dichlorophenyl ether of 3-aminopropan-1-ol in which the nitrogen is substituted by a methyl group and a prop-1-yn-3-yl group. A monoamine oxidase inhibitor, it was formerly used as an antidepressant. | clorgyline |
| clovoxamine | | clovoxamine |
| cotinine | An N-alkylpyrrolidine that consists of N-methylpyrrolidinone bearing a pyridin-3-yl substituent at position C-5 (the 5S-enantiomer). It is an alkaloid commonly found in Nicotiana tabacum. | (-)-cotinine |
| cyclobenzaprine | 5-Methylidene-5H-dibenzo[a,d]cycloheptene in which one of the hydrogens of the methylidene group is substituted by a 2-(dimethylamino)ethyl group. A centrally acting skeletal muscle relaxant, it is used as its hydrochloride salt in the symptomatic treatment of painful muscle spasm. | cyclobenzaprine |
| cyclobenzaprine hydrochloride | The hydrochloride salt of cyclobenzaprine. A centrally acting skeletal muscle relaxant, it is used in the symptomatic treatment of painful muscle spasm. | cyclobenzaprine hydrochloride |
| desipramine | A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group. | desipramine |
| desvenlafaxine | A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-hydroxyphenyl group. It is a metabolite of the drug venlafaxine. | O-desmethylvenlafaxine |
| dexamisole | A 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has R configuration. | dexamisole |
| doxepin | A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug. | doxepin |
| duloxetine hydrochloride | A duloxetine hydrochloride in which the duloxetine moiety has S configuration. | (S)-duloxetine hydrochloride |
| eicosapentaenoic acid | An icosapentaenoic acid having five cis-double bonds at positions 5, 8, 11, 14 and 17. | all-cis-5,8,11,14,17-icosapentaenoic acid |
| escitalopram | A 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile that has S-configuration at the chiral centre. It is the active enantiomer of citalopram. | escitalopram |
| etazolate | A pyrazolopyridine that is 1H-pyrazolo[3,4-b]pyridine which is substituted at positions 1, 4, and 5 by ethyl, 2-isopropylidenehydrazino, and ethoxycarbonyl groups, respectively. A phosphodiesterase IV inhibitor with antidepressant and anxiolytic properties. | etazolate |
| flibanserin | An N-alkylpiperazine that is 1-[2-(1,3-dihydro-2-oxobenzimidazol-1-yl)ethyl]piperazine in which the remaining amino proton is replaced by a 3-(trifluoromethyl)phenyl group. A multifunctional serotonin agonist and antagonist which is used for the treatment of pre-menopausal women with hypoactive sexual desire disorder. | flibanserin |
| fluoxetine | An N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine that has S configuration. [The antidepressant drug fluoxetine is a racemate comprising equimolar amounts of (R)- and (S)-fluoxetine]. | (S)-fluoxetine |
| fluvoxamine | An oxime O-ether that is benzene substituted by a (1E)-N-(2-aminoethoxy)-5-methoxypentanimidoyl group at position 1 and a trifluoromethyl group at position 4. It is a selective serotonin reuptake inhibitor that is used for the treatment of obsessive-compulsive disorder. | fluvoxamine |
| ginsenoside rb3 | A ginsenoside found in Panax species that is dammarane which is substituted by hydroxy groups at the 3beta, 12beta and 20 pro-S positions, in which the hydroxy groups at positions 3 and 20 have been converted to the corresponding beta-D-glucopyranosyl-(1->2)-beta-D-glucopyranoside and beta-D-xylopyranosyl-(1->6)-beta-D-glucopyranoside respectively, and in which a double bond has been introduced at the 24-25 position. | ginsenoside Rb3 |
| imipramine | A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom. | imipramine |
| imipramine hydrochloride | | imipramine hydrochloride |
| lamotrigine | A member of the class of 1,2,4-triazines in which the triazene skeleton is substituted by amino groups at positions 3 and 5, and by a 2,3-dichlorophenyl group at position 6. | lamotrigine |
| lespenefril | A glycosyloxyflavone that is kaempferol attached to alpha-L-rhamnopyranosyl residues at positions 3 and 7 respectively via glycosidic linkages. It has been isolated from the aerial parts of Vicia faba and Lotus edulis. | kaempferol 3,7-di-O-alpha-L-rhamnoside |
| levomefolate calcium | An organic calcium salt of (6S)-5-methyltetrahydrofolic acid. | levomefolate calcium |
| levosulpiride | An optically active form of sulpiride having (S)-configuration. The active enantiomer of the racemic drug sulpiride. Selective D2-like dopamine antagonist (Ki values are ~ 0.015. ~ 0.013, 1, ~ 45 and ~ 77 muM at D2, D3, D4, D1 and D5 receptors respectively). | (S)-(-)-sulpiride |
| lithium sulfate | A metal sulfate in which the counterion is lithium and the ratio of lithium to sulfate is 2:1. | lithium sulfate |
| lofepramine | | lofepramine |
| lofepramine hydrochloride | | lofepramine hydrochloride |
| ly 367265 | A fluoroindole that is 1H-indole in which the hydrogens at positions 3 and 6 are replaced by 1-[2-(2,2-dioxo-5,6-dihydro-4H-2lambda(6)-[1,2,5]thiadiazolo[4,3,2-ij]quinolin-1(2H)-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl and fluoro groups, respectively. It is an inhibitor of the 5-hydroxytryptamine transporter (Ki = 2.3 nM) and an antagonist of 5-hydroxytryptamine(2A) receptor (Ki = 0.81 nM). | LY-367,265 |
| memantine | A primary aliphatic amine that is the 3,5-dimethyl derivative of 1-aminoadamantane. A low to moderate affinity uncompetitive (open-channel); NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. | memantine |
| memantine hydrochloride | A hydrochloride obtained by reaction of memantine with one equivalent of hydrochloric acid. A low to moderate affinity uncompetitive (open-channel); NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. | memantine hydrochloride |
| methylene blue | An organic chloride salt having 3,7-bis(dimethylamino)phenothiazin-5-ium as the counterion. A commonly used dye that also exhibits antioxidant, antimalarial, antidepressant and cardioprotective properties. | methylene blue |
| mianserin | A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere. | mianserin |
| minaprine | | minaprine |
| moclobemide | A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression. | moclobemide |
| n-acetylphenylalanine | The N-acetyl derivative of phenylalanine. | N-acetylphenylalanine |
| nefazodone | | nefazodone |
| nisoxetine | A secondary amino compound that is N-methyl-3-phenylpropan-1-amine substituted at position 3 by a 2-methoxyphenoxy group. | nisoxetine |
| nortriptyline | An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline. | nortriptyline |
| paroxetine | A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo. | paroxetine |
| paroxetine hydrochloride | The hydrochloride salt of paroxetine. It is an antidepressant drug. | paroxetine hydrochloride |
| paroxetine maleate | A maleate salt obtained by reaction of paroxetine with one equivalent of maleic acid. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo. | paroxetine maleate |
| pioglitazone | A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity. | pioglitazone |
| protriptyline | | protriptyline |
| protriptyline hydrochloride | | protriptyline hydrochloride |
| quercetin 3-o-glucuronide | A quercetin O-glycoside that consists of quercetin attached to a beta-D-glucuronopyranosyl moiety at position 3 via a glycosidic linkage. Isolated from Salvia and Phaseolus vulgaris, it exhibits antioxidant and antidepressant activities. | miquelianin |
| ritanserin | A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action. | ritanserin |
| ro 25-6981 | A member of the class of piperidines that is 4-benzylpiperidine substituted by a 3-hydroxy-3-(4-hydroxyphenyl)-2-methylpropyl group at position 1 (the 1R,2S-stereoisomer). It is a potent antagonist of the GluN2B subunit of the N-methyl-D-aspartate (NMDA) receptor. | Ro 25-6981 |
| rolipram | A member of the lclass of pyrrolidin-2-ones that is pyrrolidin-2-one bearing a 3-(cyclopentyloxy)-4-methoxyphenyl substituent at the 4-position. It is a type IV-specific phosphodiesterase (PDE4) inhibitor. | rolipram |
| rubidium chloride | An inorganic chloride composed of rubidium and chloride ions in a 1:1 ratio. | rubidium chloride |
| salvianolic acid B | A member of the class of 1-benzofurans that is an antioxidant and free radical scavenging compound extracted from S. miltiorrhiza | salvianolic acid B |
| secoisolariciresinol | An enantiomer of secoisolariciresinol having (-)-(2R,3R)-configuration. | (-)-secoisolariciresinol |
| sertraline | A member of the class of tetralins that is tetralin which is substituted at positions 1 and 4 by a methylamino and a 3,4-dichlorophenyl group, respectively (the S,S diastereoisomer). A selective serotonin-reuptake inhibitor (SSRI), it is administered orally as the hydrochloride salt as an antidepressant for the treatment of depression, obsessive-compulsive disorder, panic disorder and post-traumatic stress disorder. | sertraline |
| sertraline hydrochloride | A hydrochloride resulting from the reaction of equimolar amounts of sertraline and hydrogen chloride. A selective serotonin-reuptake inhibitor (SSRI), it is administered orally as an antidepressant for the treatment of depression, obsessive-compulsive disorder, panic disorder and post-traumatic stress disorder. | sertraline hydrochloride |
| sulpiride | A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine. | sulpiride |
| tandospirone | A dicarboximide that is (3aR,4S,7R,7aS)-hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione which is substituted by a 4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl group at position 2. It is a potent and selective 5-HT1A receptor partial agonist (Ki = 27 nM). | tandospirone |
| tetrindole | A racemate composed of equimolar amounts of (R)- and (S)-tetrindole hydrochloride. | tetrindole hydrochloride |
| thymoquinone | A member of the class of 1,4-benzoquinones that is 1,4-bezoquinone in which the hydrogens at positions 2 and 5 are replaced by methyl and isopropyl groups, respectively. It is a natural compound isolated from Nigella sativa which has demonstrated promising chemotherapeutic activity. | thymoquinone |
| trazodone | An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group. | trazodone |
| trazodone hydrochloride | A hydrochloride salt prepared from equimolar amounts of trazodone and hydrogen chloride. | trazodone hydrochloride |
| trimipramine | A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)-2-methylpropyl group at the nitrogen atom. It is used as an antidepressant. | trimipramine |
| trimipramine maleate | | trimipramine maleate |
| tryptophan | The L-enantiomer of tryptophan. | L-tryptophan zwitterion; L-tryptophan |
| venlafaxine | A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group. | venlafaxine |
| vilazodone | A 1-benzofuran that is 5-(piperazin-1-yl}-1-benzofuran-2-carboxamide having a (5-cyanoindol-3-yl)butyl group attached at position N-4 on the piperazine ring. Used for the treatment of major depressive disorder. | vilazodone |
| vilazodone hydrochloride | A hydrochloride obtained by reaction of vilazodone with one equivalent of hydrochloric acid. Used for the treatment of major depressive disorder. | vilazodone hydrochloride |
| vortioxetine | An N-arylpiperazine in which the aryl group is specified as 2-[(2,4-dimethylphenyl)sulfanyl]phenyl. Used (as its hydrobromide salt) for treatment of major depressive disorder. | vortioxetine |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 21.4157 | 1 | 7 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 20.4023 | 1 | 7 |
| 2,3-bisphosphoglycerate-independent phosphoglycerate mutase | Leishmania major strain Friedlin | Potency | 0.0478 | 1 | 1 |
| 67.9K protein | Vaccinia virus | Potency | 13.5501 | 2 | 16 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 17.8561 | 4 | 20 |
| acid sphingomyelinase | Homo sapiens (human) | Potency | 19.9526 | 1 | 1 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 11.2678 | 2 | 10 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 22.8887 | 1 | 14 |
| alpha-galactosidase | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 8.4845 | 1 | 3 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 31.4658 | 1 | 4 |
| AR protein | Homo sapiens (human) | Potency | 24.7405 | 10 | 107 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 27.6703 | 2 | 15 |
| arylsulfatase A | Homo sapiens (human) | Potency | 7.9741 | 1 | 18 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 17.5790 | 3 | 19 |
| Ataxin-2 | Homo sapiens (human) | Potency | 20.3460 | 2 | 24 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 16.9186 | 2 | 18 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 27.2686 | 1 | 5 |
| atrial natriuretic peptide receptor 1 precursor | Homo sapiens (human) | Potency | 14.4468 | 1 | 4 |
| atrial natriuretic peptide receptor 2 precursor | Homo sapiens (human) | Potency | 16.4952 | 1 | 14 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 23.1787 | 2 | 15 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 54.4122 | 1 | 8 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 31.3286 | 1 | 7 |
| caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 33.4915 | 1 | 1 |
| caspase-3 | Homo sapiens (human) | Potency | 31.3286 | 1 | 7 |
| Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 33.4915 | 1 | 1 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 28.4463 | 2 | 28 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 18.8973 | 2 | 25 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 27.1780 | 1 | 17 |
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 16.8780 | 2 | 3 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 16.8962 | 2 | 10 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 30.6308 | 2 | 4 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 30.0584 | 2 | 11 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 23.5446 | 2 | 14 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 33.5239 | 1 | 7 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 36.2521 | 3 | 17 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 15.1294 | 1 | 2 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 23.8056 | 2 | 8 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 23.5446 | 2 | 14 |
| chaperonin GroEL | Methanococcus maripaludis S2 | Potency | 100.0000 | 1 | 1 |
| chaperonin-containing TCP-1 beta subunit homolog | Homo sapiens (human) | Potency | 22.3872 | 1 | 1 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 50.5702 | 2 | 25 |
| CREB-binding protein | Homo sapiens (human) | Potency | 5.4415 | 3 | 3 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 7.1207 | 1 | 13 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 18.6895 | 1 | 6 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 9.9869 | 1 | 11 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 7.3710 | 1 | 31 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 11.0422 | 1 | 39 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 15.3757 | 2 | 62 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 15.2085 | 2 | 32 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 22.9557 | 1 | 13 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 5.1807 | 3 | 43 |
| D(1A) dopamine receptor | Sus scrofa (pig) | Potency | 20.9321 | 1 | 11 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 19.9526 | 1 | 1 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 56.2341 | 1 | 1 |
| DNA polymerase III, partial | Bacillus subtilis | Potency | 21.1923 | 1 | 1 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 21.3088 | 1 | 5 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 6.9212 | 1 | 3 |
| dopamine D1 receptor | Homo sapiens (human) | Potency | 3.8832 | 1 | 2 |
| endonuclease IV | Escherichia coli | Potency | 15.4701 | 1 | 5 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 33.7562 | 10 | 89 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 25.8785 | 2 | 22 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 26.6751 | 10 | 92 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 27.7144 | 2 | 48 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 16.3515 | 4 | 31 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 30.4291 | 4 | 13 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 8.3703 | 2 | 10 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 33.6018 | 1 | 13 |
| G | Vesicular stomatitis virus | Potency | 9.9869 | 1 | 11 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 15.3757 | 1 | 31 |
| GALC protein | Homo sapiens (human) | Potency | 0.6580 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 15.3757 | 1 | 31 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 15.3757 | 1 | 31 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 15.3757 | 1 | 31 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 15.3757 | 1 | 31 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 15.3757 | 1 | 31 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 15.3757 | 1 | 31 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 15.3757 | 1 | 31 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 15.3757 | 1 | 31 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 15.3757 | 1 | 31 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 15.3757 | 1 | 31 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 15.3757 | 1 | 31 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 15.3757 | 1 | 31 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 15.3757 | 1 | 31 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 15.3757 | 1 | 31 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 15.3757 | 1 | 31 |
| geminin | Homo sapiens (human) | Potency | 11.9116 | 4 | 51 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 13.0308 | 2 | 47 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 9.8489 | 2 | 18 |
| GLS protein | Homo sapiens (human) | Potency | 9.9196 | 2 | 14 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 20.6725 | 1 | 5 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 26.4426 | 3 | 31 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 31.6408 | 1 | 7 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 0.5012 | 1 | 1 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 10.9214 | 1 | 3 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 19.0919 | 1 | 2 |
| heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) | Homo sapiens (human) | Potency | 41.1109 | 1 | 3 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 38.2479 | 2 | 11 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 16.1165 | 2 | 78 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 26.4925 | 1 | 8 |
| histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 12.3066 | 2 | 4 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 53.0969 | 2 | 11 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 48.0592 | 1 | 7 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 9.9869 | 1 | 11 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 28.8304 | 2 | 5 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 19.9526 | 1 | 1 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 28.5587 | 2 | 10 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 15.9915 | 2 | 12 |
| IDH1 | Homo sapiens (human) | Potency | 16.1578 | 1 | 17 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 28.0492 | 2 | 4 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 9.9869 | 1 | 22 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 5.1963 | 2 | 17 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 23.0667 | 1 | 9 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 23.0667 | 1 | 9 |
| Interferon beta | Homo sapiens (human) | Potency | 16.9031 | 3 | 30 |
| isocitrate dehydrogenase 1, partial | Homo sapiens (human) | Potency | 51.1190 | 1 | 2 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 11.9316 | 2 | 28 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 17.0190 | 1 | 10 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 19.2571 | 2 | 4 |
| luciferase | Photuris pensylvanica (Pennsylania firefly) | Potency | 10.0000 | 1 | 1 |
| luteinizing hormone receptor | Homo sapiens (human) | Potency | 84.9214 | 1 | 1 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 24.3734 | 1 | 10 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 17.6974 | 2 | 15 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 17.9620 | 2 | 18 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 6.7648 | 2 | 38 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 8.4719 | 1 | 2 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 9.5534 | 3 | 10 |
| NFKB1 protein, partial | Homo sapiens (human) | Potency | 6.6057 | 2 | 20 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 12.0541 | 1 | 6 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 51.0999 | 1 | 6 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 23.9604 | 4 | 24 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 24.7152 | 1 | 4 |
| nuclear factor NF-kappa-B p105 subunit isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 24.1210 | 1 | 8 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 22.3245 | 2 | 14 |
| nuclear receptor subfamily 1, group I, member 2 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1 | 1 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 23.4838 | 3 | 33 |
| Ornithine decarboxylase | Rattus norvegicus (Norway rat) | Potency | 0.0063 | 1 | 2 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 17.9008 | 1 | 2 |
| Parkin | Homo sapiens (human) | Potency | 29.6593 | 2 | 2 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 40.6224 | 2 | 5 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 21.1565 | 2 | 12 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 53.3956 | 1 | 14 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 23.7199 | 3 | 17 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 29.4098 | 4 | 17 |
| phosphoglycerate kinase | Trypanosoma brucei brucei TREU927 | Potency | 17.7828 | 1 | 1 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 62.4636 | 3 | 17 |
| PINK1 | Homo sapiens (human) | Potency | 50.1187 | 1 | 1 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 7.3248 | 1 | 9 |
| polyprotein | Zika virus | Potency | 33.6018 | 1 | 13 |
| polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | Potency | 14.7928 | 1 | 2 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 15.3446 | 1 | 30 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 11.7158 | 1 | 28 |
| PPM1D protein | Homo sapiens (human) | Potency | 18.8797 | 1 | 10 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 15.7109 | 3 | 23 |
| progesterone receptor | Homo sapiens (human) | Potency | 27.6430 | 2 | 24 |
| pyruvate kinase PKM isoform a | Homo sapiens (human) | Potency | 39.8107 | 2 | 2 |
| pyruvate kinase PKM isoform b | Homo sapiens (human) | Potency | 0.0063 | 2 | 3 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 61.0549 | 2 | 3 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 20.2639 | 2 | 28 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 58.6908 | 1 | 7 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 14.5824 | 1 | 12 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 27.1114 | 3 | 50 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 20.3940 | 3 | 24 |
| serine-protein kinase ATM isoform a | Homo sapiens (human) | Potency | 13.0258 | 4 | 4 |
| serine/threonine-protein kinase mTOR isoform 1 | Homo sapiens (human) | Potency | 20.4049 | 4 | 31 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 24.5238 | 3 | 5 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 24.5238 | 3 | 5 |
| Smad3 | Homo sapiens (human) | Potency | 26.7458 | 1 | 11 |
| snurportin-1 | Homo sapiens (human) | Potency | 28.0492 | 2 | 4 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 28.6427 | 2 | 18 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 16.1302 | 1 | 17 |
| T cell receptor, partial | Homo sapiens (human) | Potency | 6.2841 | 1 | 1 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 24.7710 | 1 | 4 |
| TDP1 protein | Homo sapiens (human) | Potency | 18.8022 | 2 | 96 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 23.6224 | 1 | 3 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 25.2958 | 4 | 37 |
| Thrombopoietin | Homo sapiens (human) | Potency | 11.8941 | 2 | 24 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 18.8518 | 3 | 47 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 17.8983 | 4 | 7 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 23.6884 | 7 | 60 |
| thyrotropin-releasing hormone receptor | Homo sapiens (human) | Potency | 31.9362 | 2 | 4 |
| transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | Potency | 19.4538 | 1 | 5 |
| TSHR protein | Homo sapiens (human) | Potency | 15.5035 | 2 | 2 |
| tyrosine-protein kinase Yes | Homo sapiens (human) | Potency | 1.7291 | 1 | 1 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 19.9526 | 1 | 1 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 7.3248 | 1 | 9 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 7.3248 | 1 | 9 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 40.5328 | 3 | 18 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 14.1958 | 2 | 40 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 23.9155 | 3 | 12 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 44.6597 | 5 | 15 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 31.6408 | 1 | 7 |
| Vpr | Human immunodeficiency virus 1 | Potency | 39.8107 | 1 | 1 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 3-oxo-5-alpha-steroid 4-dehydrogenase 2 | Homo sapiens (human) | IC50 | 0.8000 | 1 | 1 |
| 3',5'-cyclic-AMP phosphodiesterase | Sus scrofa (pig) | IC50 | 3.6300 | 1 | 1 |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | IC50 | 0.1991 | 4 | 4 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | IC50 | 0.9523 | 3 | 13 |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | Ki | 0.6761 | 15 | 18 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | Ki | 0.9782 | 8 | 12 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | IC50 | 1.3368 | 3 | 13 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | Ki | 1.6814 | 5 | 9 |
| 5-hydroxytryptamine receptor 1D | Homo sapiens (human) | IC50 | 0.3802 | 2 | 2 |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | IC50 | 1.2266 | 2 | 8 |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | Ki | 2.2267 | 3 | 3 |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | IC50 | 0.8304 | 1 | 7 |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | Ki | 2.2267 | 3 | 3 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | IC50 | 0.2291 | 6 | 15 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | IC50 | 0.4332 | 9 | 17 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | Ki | 0.0412 | 20 | 33 |
| 5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | Ki | 0.0008 | 1 | 1 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | Ki | 1.9365 | 12 | 14 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | IC50 | 0.3690 | 2 | 11 |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | IC50 | 0.4849 | 6 | 12 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | Ki | 0.3222 | 1 | 8 |
| 5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | Ki | 0.0008 | 1 | 1 |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | Ki | 3.3806 | 6 | 8 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | IC50 | 0.1080 | 3 | 12 |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | IC50 | 0.6015 | 7 | 13 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | Ki | 0.0380 | 13 | 23 |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | Ki | 3.0052 | 7 | 9 |
| 5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | Ki | 0.0804 | 2 | 2 |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | IC50 | 1.4125 | 2 | 2 |
| 5-hydroxytryptamine receptor 3A | Mus musculus (house mouse) | IC50 | 1.4125 | 1 | 1 |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | IC50 | 1.2641 | 2 | 8 |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | Ki | 0.0037 | 1 | 1 |
| 5-hydroxytryptamine receptor 3A | Mus musculus (house mouse) | Ki | 0.2520 | 1 | 1 |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | Ki | 0.0700 | 1 | 1 |
| 5-hydroxytryptamine receptor 3B | Homo sapiens (human) | IC50 | 1.4125 | 2 | 2 |
| 5-hydroxytryptamine receptor 3B | Mus musculus (house mouse) | IC50 | 1.4125 | 1 | 1 |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | IC50 | 1.2641 | 2 | 8 |
| 5-hydroxytryptamine receptor 3B | Mus musculus (house mouse) | Ki | 0.2520 | 1 | 1 |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | Ki | 0.0700 | 1 | 1 |
| 5-hydroxytryptamine receptor 3C | Homo sapiens (human) | IC50 | 1.4125 | 2 | 2 |
| 5-hydroxytryptamine receptor 3D | Homo sapiens (human) | IC50 | 1.4125 | 2 | 2 |
| 5-hydroxytryptamine receptor 3E | Homo sapiens (human) | IC50 | 1.4125 | 2 | 2 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | IC50 | 0.1601 | 1 | 8 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | Ki | 0.0838 | 1 | 8 |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | IC50 | 0.7581 | 2 | 8 |
| 5-hydroxytryptamine receptor 5A | Rattus norvegicus (Norway rat) | IC50 | 0.8304 | 1 | 7 |
| 5-hydroxytryptamine receptor 5B | Rattus norvegicus (Norway rat) | IC50 | 0.8304 | 1 | 7 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | IC50 | 0.2367 | 1 | 6 |
| 5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | IC50 | 1.1016 | 2 | 8 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | Ki | 0.9489 | 4 | 13 |
| 5-hydroxytryptamine receptor 7 | Cavia porcellus (domestic guinea pig) | IC50 | 27.5000 | 1 | 12 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | IC50 | 0.1148 | 1 | 1 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | Ki | 1.6814 | 12 | 16 |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | IC50 | 1.1016 | 2 | 8 |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | Ki | 0.0485 | 2 | 4 |
| Acetylcholine receptor subunit alpha | Homo sapiens (human) | IC50 | 5.2693 | 3 | 3 |
| Acetylcholine receptor subunit beta | Homo sapiens (human) | IC50 | 5.2693 | 3 | 3 |
| Acetylcholine receptor subunit delta | Homo sapiens (human) | IC50 | 5.2693 | 3 | 3 |
| Acetylcholine receptor subunit gamma | Homo sapiens (human) | IC50 | 5.2693 | 3 | 3 |
| Acetylcholinesterase | Electrophorus electricus (electric eel) | IC50 | 370.0000 | 3 | 3 |
| Acetylcholinesterase | Homo sapiens (human) | IC50 | 146.5105 | 4 | 4 |
| Acetylcholinesterase | Mus musculus (house mouse) | IC50 | 21.3000 | 1 | 1 |
| Acetylcholinesterase | Rattus norvegicus (Norway rat) | IC50 | 21.3000 | 2 | 2 |
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | IC50 | 100.0000 | 1 | 1 |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | IC50 | 100.0000 | 1 | 5 |
| Adenosine receptor A2b | Rattus norvegicus (Norway rat) | IC50 | 100.0000 | 1 | 5 |
| Advanced glycosylation end product-specific receptor | Homo sapiens (human) | IC50 | 200.0000 | 1 | 1 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | IC50 | 0.4534 | 1 | 9 |
| Aldo-keto reductase family 1 member B1 | Bos taurus (cattle) | Ki | 0.0004 | 1 | 1 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | Ki | 0.4495 | 1 | 9 |
| Alkaline phosphatase, tissue-nonspecific isozyme | Homo sapiens (human) | IC50 | 5.0000 | 1 | 1 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | IC50 | 0.9316 | 3 | 3 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 0.1125 | 8 | 13 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | Ki | 0.1030 | 2 | 2 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 1.7392 | 6 | 9 |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | IC50 | 1.9800 | 1 | 1 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 0.2286 | 6 | 6 |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | Ki | 0.1800 | 1 | 1 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 1.7392 | 6 | 9 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | IC50 | 0.4138 | 2 | 8 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 0.2736 | 5 | 5 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | Ki | 0.1041 | 2 | 8 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 1.7392 | 6 | 9 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | IC50 | 0.8487 | 4 | 17 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 1.7992 | 2 | 2 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | Ki | 0.3158 | 2 | 10 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 2.7123 | 3 | 6 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | IC50 | 0.4970 | 3 | 15 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 1.7992 | 2 | 2 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | Ki | 0.0831 | 1 | 8 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 2.7123 | 3 | 6 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | IC50 | 1.0919 | 5 | 17 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 1.7992 | 2 | 2 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | Ki | 0.2019 | 2 | 9 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 2.7123 | 3 | 6 |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | IC50 | 67.8588 | 117 | 147 |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | Ki | 0.2691 | 11 | 13 |
| Amine oxidase [flavin-containing] A | Bos taurus (cattle) | IC50 | 5.8845 | 6 | 8 |
| Amine oxidase [flavin-containing] A | Rattus norvegicus (Norway rat) | IC50 | 127.2094 | 10 | 12 |
| Amine oxidase [flavin-containing] A | Bos taurus (cattle) | Ki | 17.9808 | 5 | 12 |
| Amine oxidase [flavin-containing] A | Rattus norvegicus (Norway rat) | Ki | 5.8854 | 2 | 2 |
| Amine oxidase [flavin-containing] B | Bos taurus (cattle) | IC50 | 4,383.0000 | 6 | 7 |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | IC50 | 202.7803 | 83 | 89 |
| Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | IC50 | 255.2558 | 7 | 7 |
| Amine oxidase [flavin-containing] B | Bos taurus (cattle) | Ki | 66.7962 | 5 | 12 |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | Ki | 8.6772 | 12 | 14 |
| Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | Ki | 0.8567 | 3 | 3 |
| Amyloid-beta precursor protein | Homo sapiens (human) | IC50 | 0.5000 | 1 | 1 |
| Androgen receptor | Rattus norvegicus (Norway rat) | Ki | 2.2900 | 1 | 1 |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | IC50 | 77.3643 | 3 | 6 |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | Ki | 13.1465 | 1 | 4 |
| Angiotensin-converting enzyme | Rattus norvegicus (Norway rat) | Ki | 0.5000 | 1 | 3 |
| Apoptotic peptidase activating factor 1 | Homo sapiens (human) | IC50 | 57.7500 | 2 | 2 |
| Aromatase | Homo sapiens (human) | IC50 | 53.2000 | 1 | 1 |
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 20 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | IC50 | 22.1000 | 2 | 3 |
| Beta-2 adrenergic receptor | Cavia porcellus (domestic guinea pig) | IC50 | 0.0270 | 1 | 1 |
| Beta-adrenergic receptor kinase 1 | Bos taurus (cattle) | IC50 | 1.1533 | 3 | 3 |
| Beta-adrenergic receptor kinase 1 | Homo sapiens (human) | IC50 | 4.5600 | 6 | 6 |
| Beta-carbonic anhydrase 1 | Mycobacterium tuberculosis H37Rv | Ki | 2.3000 | 1 | 1 |
| Bifunctional epoxide hydrolase 2 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Bile salt export pump | Homo sapiens (human) | IC50 | 165.1746 | 7 | 55 |
| Bile salt export pump | Rattus norvegicus (Norway rat) | IC50 | 339.8000 | 1 | 3 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A | Homo sapiens (human) | IC50 | 112.5000 | 4 | 4 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A | Homo sapiens (human) | Ki | 130.0000 | 2 | 2 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A | Bos taurus (cattle) | IC50 | 1,355.0000 | 2 | 2 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B | Bos taurus (cattle) | IC50 | 1,355.0000 | 2 | 2 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B | Homo sapiens (human) | IC50 | 149.3592 | 4 | 13 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B | Rattus norvegicus (Norway rat) | IC50 | 100.0000 | 1 | 1 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B | Homo sapiens (human) | Ki | 130.0000 | 2 | 2 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C | Homo sapiens (human) | IC50 | 133.3333 | 3 | 3 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C | Rattus norvegicus (Norway rat) | IC50 | 100.0000 | 1 | 1 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C | Homo sapiens (human) | Ki | 130.0000 | 2 | 2 |
| Calcium/calmodulin-dependent protein kinase type II subunit alpha | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Calcium/calmodulin-dependent protein kinase type II subunit beta | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Calcium/calmodulin-dependent protein kinase type II subunit delta | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Calcium/calmodulin-dependent protein kinase type II subunit gamma | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A | Homo sapiens (human) | IC50 | 141.6064 | 2 | 11 |
| cAMP-dependent protein kinase catalytic subunit alpha | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| cAMP-dependent protein kinase catalytic subunit beta | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| cAMP-dependent protein kinase catalytic subunit gamma | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | IC50 | 2.1363 | 53 | 55 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Rattus norvegicus (Norway rat) | IC50 | 0.7287 | 11 | 16 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | Ki | 1.7915 | 12 | 16 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Rattus norvegicus (Norway rat) | Ki | 0.0110 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Homo sapiens (human) | IC50 | 17.0443 | 91 | 102 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Rattus norvegicus (Norway rat) | IC50 | 0.8447 | 12 | 17 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Homo sapiens (human) | Ki | 1.2577 | 14 | 18 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Rattus norvegicus (Norway rat) | Ki | 0.0110 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Homo sapiens (human) | IC50 | 3.6862 | 50 | 52 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Rattus norvegicus (Norway rat) | IC50 | 0.7287 | 11 | 16 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Homo sapiens (human) | Ki | 0.2264 | 9 | 9 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Rattus norvegicus (Norway rat) | Ki | 0.0110 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | IC50 | 15.8189 | 104 | 117 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | Ki | 1.4418 | 18 | 22 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Rattus norvegicus (Norway rat) | IC50 | 0.7287 | 11 | 16 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Rattus norvegicus (Norway rat) | Ki | 0.0110 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 7B | Homo sapiens (human) | IC50 | 154.1670 | 1 | 10 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 17 |
| Cannabinoid receptor 1 | Homo sapiens (human) | IC50 | 0.0892 | 7 | 7 |
| Cannabinoid receptor 1 | Homo sapiens (human) | Ki | 0.0167 | 7 | 8 |
| Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | Ki | 0.0029 | 2 | 3 |
| Cannabinoid receptor 2 | Homo sapiens (human) | Ki | 0.3703 | 7 | 8 |
| Carbonic anhydrase | Candida albicans SC5314 | Ki | 0.7600 | 2 | 2 |
| Carbonic anhydrase | Helicobacter pylori 26695 | Ki | 0.1915 | 2 | 2 |
| Carbonic anhydrase | Saccharomyces cerevisiae S288C | Ki | 0.1240 | 1 | 1 |
| Carbonic anhydrase | Stylophora pistillata | Ki | 0.4150 | 1 | 1 |
| Carbonic anhydrase | Anopheles gambiae (African malaria mosquito) | Ki | 0.0295 | 1 | 1 |
| Carbonic anhydrase | Astrosclera willeyana | Ki | 0.3780 | 1 | 1 |
| Carbonic anhydrase | Cryptococcus neoformans var. grubii | Ki | 0.8120 | 1 | 1 |
| Carbonic anhydrase | Nakaseomyces glabratus CBS 138 | Ki | 0.1130 | 1 | 1 |
| Carbonic anhydrase | Stylophora pistillata | Ki | 0.4300 | 2 | 2 |
| Carbonic anhydrase | Sulfurihydrogenibium sp. YO3AOP1 | Ki | 0.0674 | 1 | 1 |
| Carbonic anhydrase 1 | Homo sapiens (human) | IC50 | 1.2000 | 1 | 1 |
| Carbonic anhydrase 1 | Homo sapiens (human) | Ki | 4.2183 | 33 | 35 |
| Carbonic anhydrase 12 | Homo sapiens (human) | Ki | 0.0039 | 3 | 3 |
| Carbonic anhydrase 15 | Mus musculus (house mouse) | Ki | 0.0730 | 1 | 1 |
| Carbonic anhydrase 2 | Homo sapiens (human) | IC50 | 0.0770 | 2 | 2 |
| Carbonic anhydrase 2 | Homo sapiens (human) | Ki | 0.3170 | 40 | 43 |
| Carbonic anhydrase 2 | Mycobacterium tuberculosis H37Rv | Ki | 0.2660 | 1 | 1 |
| Carbonic anhydrase 3 | Homo sapiens (human) | Ki | 10.6000 | 1 | 1 |
| Carbonic anhydrase 4 | Bos taurus (cattle) | IC50 | 0.6200 | 1 | 1 |
| Carbonic anhydrase 5A, mitochondrial | Homo sapiens (human) | Ki | 0.1740 | 1 | 1 |
| Carbonic anhydrase 5B, mitochondrial | Homo sapiens (human) | Ki | 0.0180 | 1 | 1 |
| Carbonic anhydrase 6 | Homo sapiens (human) | Ki | 2.0072 | 4 | 6 |
| Carbonic anhydrase 7 | Homo sapiens (human) | Ki | 2.4212 | 3 | 3 |
| Carbonic anhydrase 9 | Homo sapiens (human) | Ki | 0.0409 | 6 | 7 |
| Carbonic anhydrase, alpha family | Hydrogenovibrio crunogenus XCL-2 | Ki | 0.8730 | 1 | 1 |
| Carnitine O-palmitoyltransferase 1, liver isoform | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Carnitine O-palmitoyltransferase 2, mitochondrial | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Carnitine O-palmitoyltransferase 2, mitochondrial | Rattus norvegicus (Norway rat) | IC50 | 100.0000 | 1 | 1 |
| Caspase-1 | Homo sapiens (human) | IC50 | 1.0800 | 1 | 1 |
| caspase-3 isoform a preproprotein | Homo sapiens (human) | IC50 | 17.0000 | 1 | 1 |
| caspase-9 isoform alpha precursor | Homo sapiens (human) | IC50 | 17.0000 | 1 | 1 |
| CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | IC50 | 8.6500 | 1 | 1 |
| CDGSH iron-sulfur domain-containing protein 1 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 1 |
| CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | Ki | 0.3700 | 1 | 1 |
| CDGSH iron-sulfur domain-containing protein 2 | Homo sapiens (human) | IC50 | 4.8000 | 1 | 1 |
| cGMP-dependent 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | IC50 | 116.8544 | 6 | 16 |
| cGMP-dependent 3',5'-cyclic phosphodiesterase | Rattus norvegicus (Norway rat) | IC50 | 10.0000 | 1 | 1 |
| cGMP-dependent 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | Ki | 200.0000 | 1 | 1 |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | IC50 | 122.0000 | 11 | 12 |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | Ki | 106.0000 | 2 | 2 |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | IC50 | 145.1835 | 11 | 20 |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | Ki | 106.0000 | 2 | 2 |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Bos taurus (cattle) | IC50 | 88.6667 | 3 | 3 |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | IC50 | 115.0217 | 8 | 18 |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | Ki | 200.0000 | 1 | 1 |
| Chain A, Protein (peroxisome Proliferator Activated Receptor (ppar-delta)) | Homo sapiens (human) | IC50 | 4.0000 | 1 | 1 |
| Chain E, Fibrin beta chain | Homo sapiens (human) | IC50 | 46.2655 | 2 | 2 |
| Chloroquine resistance transporter | Plasmodium falciparum (malaria parasite P. falciparum) | IC50 | 54.0000 | 1 | 1 |
| Cholinesterase | Equus caballus (horse) | IC50 | 255.0000 | 2 | 2 |
| Cholinesterase | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| Coagulation factor VII | Homo sapiens (human) | IC50 | 78.0000 | 1 | 1 |
| Cruzipain | Trypanosoma cruzi | IC50 | 70.0000 | 2 | 2 |
| Cytochrome P450 1A1 | Homo sapiens (human) | IC50 | 0.0079 | 1 | 1 |
| Cytochrome P450 1A2 | Homo sapiens (human) | IC50 | 2,700.0040 | 2 | 2 |
| Cytochrome P450 1A2 | Homo sapiens (human) | Ki | 7.6320 | 1 | 1 |
| Cytochrome P450 1A2 | Rattus norvegicus (Norway rat) | Ki | 57.4000 | 1 | 1 |
| Cytochrome P450 2A5 | Mus musculus (house mouse) | IC50 | 1,500.0000 | 1 | 1 |
| Cytochrome P450 2A6 | Homo sapiens (human) | IC50 | 11,933.3333 | 2 | 3 |
| Cytochrome P450 2B1 | Rattus norvegicus (Norway rat) | Ki | 1.5000 | 1 | 1 |
| Cytochrome P450 2C19 | Homo sapiens (human) | IC50 | 1.5771 | 2 | 4 |
| Cytochrome P450 2C8 | Homo sapiens (human) | Ki | 49.9000 | 1 | 1 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 | 29.9794 | 3 | 6 |
| Cytochrome P450 2C9 | Homo sapiens (human) | Ki | 8.5000 | 1 | 1 |
| Cytochrome P450 2D1 | Rattus norvegicus (Norway rat) | IC50 | 204.0000 | 1 | 1 |
| Cytochrome P450 2D26 | Rattus norvegicus (Norway rat) | IC50 | 1.9000 | 1 | 1 |
| Cytochrome P450 2D3 | Rattus norvegicus (Norway rat) | IC50 | 14.2000 | 1 | 1 |
| Cytochrome P450 2D4 | Rattus norvegicus (Norway rat) | IC50 | 19.3000 | 1 | 1 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 | 9.8579 | 9 | 13 |
| Cytochrome P450 2D6 | Homo sapiens (human) | Ki | 8.6750 | 3 | 4 |
| Cytochrome P450 2J2 | Homo sapiens (human) | IC50 | 42.1250 | 1 | 4 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 | 93.8892 | 5 | 5 |
| Cytochrome P450 3A4 | Homo sapiens (human) | Ki | 1.0000 | 1 | 3 |
| D | Rattus norvegicus (Norway rat) | IC50 | 0.8881 | 2 | 6 |
| D | Bos taurus (cattle) | Ki | 50.0000 | 2 | 2 |
| D | Rattus norvegicus (Norway rat) | Ki | 1.5100 | 2 | 2 |
| D(1A) dopamine receptor | Homo sapiens (human) | IC50 | 0.6050 | 1 | 6 |
| D(1A) dopamine receptor | Homo sapiens (human) | Ki | 0.2720 | 2 | 7 |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.3880 | 1 | 5 |
| D(1B) dopamine receptor | Homo sapiens (human) | Ki | 0.1700 | 1 | 1 |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 1.6000 | 1 | 1 |
| D(2) dopamine receptor | Canis lupus familiaris (dog) | IC50 | 0.2000 | 1 | 1 |
| D(2) dopamine receptor | Homo sapiens (human) | IC50 | 1.7551 | 8 | 12 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.5274 | 15 | 21 |
| D(2) dopamine receptor | Homo sapiens (human) | Ki | 0.3356 | 12 | 16 |
| D(2) dopamine receptor | Mus musculus (house mouse) | Ki | 0.7260 | 1 | 1 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 0.2864 | 10 | 17 |
| D(3) dopamine receptor | Homo sapiens (human) | IC50 | 1.2058 | 5 | 12 |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.3352 | 2 | 6 |
| D(3) dopamine receptor | Homo sapiens (human) | Ki | 0.3864 | 7 | 14 |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 1.5620 | 2 | 2 |
| D(4) dopamine receptor | Homo sapiens (human) | IC50 | 3.3113 | 2 | 2 |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.8900 | 2 | 6 |
| D(4) dopamine receptor | Homo sapiens (human) | Ki | 1.2682 | 5 | 5 |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 1.6000 | 1 | 1 |
| Delta carbonic anhydrase | Conticribra weissflogii | Ki | 0.2590 | 1 | 1 |
| Delta-type opioid receptor | Mus musculus (house mouse) | IC50 | 5.4087 | 3 | 3 |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | IC50 | 1.5000 | 1 | 1 |
| Delta-type opioid receptor | Mus musculus (house mouse) | Ki | 0.6200 | 2 | 2 |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | Ki | 0.0400 | 1 | 1 |
| Diacylglycerol kinase alpha | Homo sapiens (human) | IC50 | 12.8500 | 2 | 2 |
| Dihydrofolate reductase | Escherichia coli K-12 | IC50 | 348.9000 | 1 | 1 |
| Dihydrofolate reductase | Homo sapiens (human) | IC50 | 6,500.0000 | 1 | 1 |
| Dihydrofolate reductase | Escherichia coli K-12 | Ki | 15.2400 | 1 | 1 |
| Dihydrofolate reductase | Homo sapiens (human) | Ki | 2,800.0000 | 1 | 1 |
| Dihydrolipoyl dehydrogenase | Plasmodium falciparum (malaria parasite P. falciparum) | IC50 | 1,000.0000 | 1 | 1 |
| Dihydrolipoyl dehydrogenase, mitochondrial | Sus scrofa (pig) | IC50 | 1,000.0000 | 1 | 1 |
| DNA topoisomerase 1 | Homo sapiens (human) | IC50 | 250.0000 | 1 | 1 |
| DNA topoisomerase 2-alpha | Homo sapiens (human) | IC50 | 250.0000 | 1 | 1 |
| Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A | Homo sapiens (human) | IC50 | 141.6064 | 2 | 11 |
| Endothelin receptor type B | Homo sapiens (human) | Ki | 0.0395 | 2 | 4 |
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | Ki | 0.0395 | 1 | 2 |
| Endothelin-1 receptor | Homo sapiens (human) | IC50 | 0.1148 | 1 | 1 |
| Endothelin-1 receptor | Sus scrofa (pig) | Ki | 0.0045 | 1 | 1 |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Francisella tularensis subsp. tularensis SCHU S4 | IC50 | 79.0000 | 1 | 1 |
| G protein-coupled receptor kinase 5 | Bos taurus (cattle) | IC50 | 150.7250 | 4 | 4 |
| G protein-coupled receptor kinase 5 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| G-protein coupled receptor | Apis mellifera (honey bee) | IC50 | 73.0000 | 1 | 1 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | IC50 | 0.0985 | 4 | 4 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Ki | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Homo sapiens (human) | IC50 | 0.0220 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Mus musculus (house mouse) | IC50 | 0.0740 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | IC50 | 0.0985 | 4 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Ki | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Homo sapiens (human) | IC50 | 0.0220 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | IC50 | 0.0985 | 4 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Ki | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Homo sapiens (human) | IC50 | 0.0220 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | IC50 | 0.0985 | 4 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Ki | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Homo sapiens (human) | IC50 | 0.0220 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | IC50 | 0.0985 | 4 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Ki | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Homo sapiens (human) | IC50 | 0.0220 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | IC50 | 0.0985 | 4 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Ki | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Homo sapiens (human) | IC50 | 0.0220 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | IC50 | 0.0985 | 4 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Ki | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Homo sapiens (human) | IC50 | 0.0220 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | IC50 | 0.0985 | 4 | 4 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Ki | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Homo sapiens (human) | IC50 | 0.0220 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | IC50 | 0.0985 | 4 | 4 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Ki | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Homo sapiens (human) | IC50 | 0.0220 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | IC50 | 0.0985 | 4 | 4 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Ki | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit delta | Homo sapiens (human) | IC50 | 0.0220 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | IC50 | 0.0985 | 4 | 4 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Ki | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit epsilon | Homo sapiens (human) | IC50 | 0.0220 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | IC50 | 0.0985 | 4 | 4 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Ki | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Homo sapiens (human) | IC50 | 0.0220 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | IC50 | 0.0985 | 4 | 4 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Ki | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Homo sapiens (human) | IC50 | 0.0220 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | IC50 | 0.0985 | 4 | 4 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Ki | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Homo sapiens (human) | IC50 | 0.0220 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | IC50 | 0.0985 | 4 | 4 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Ki | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit pi | Homo sapiens (human) | IC50 | 0.0220 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | IC50 | 0.0985 | 4 | 4 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Ki | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit theta | Homo sapiens (human) | IC50 | 0.0220 | 1 | 1 |
| Glucose-6-phosphate 1-dehydrogenase | Homo sapiens (human) | IC50 | 66.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | IC50 | 3.0425 | 15 | 15 |
| Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | Ki | 0.3503 | 6 | 6 |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | IC50 | 13.0282 | 20 | 21 |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | Ki | 0.7000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | IC50 | 7.6284 | 10 | 10 |
| Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | Ki | 0.2729 | 4 | 4 |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | IC50 | 16.9656 | 16 | 16 |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | Ki | 0.7000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2B | Homo sapiens (human) | IC50 | 2.1384 | 10 | 10 |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | IC50 | 10.9691 | 19 | 20 |
| Glutamate receptor ionotropic, NMDA 2B | Homo sapiens (human) | Ki | 0.3249 | 7 | 7 |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | Ki | 0.7000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2C | Homo sapiens (human) | IC50 | 0.0060 | 2 | 2 |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | IC50 | 16.6980 | 13 | 13 |
| Glutamate receptor ionotropic, NMDA 2C | Homo sapiens (human) | Ki | 0.2729 | 4 | 4 |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | Ki | 0.7000 | 1 | 2 |
| Glutamate receptor ionotropic, NMDA 2D | Homo sapiens (human) | IC50 | 0.0060 | 2 | 2 |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | IC50 | 16.6980 | 13 | 13 |
| Glutamate receptor ionotropic, NMDA 2D | Homo sapiens (human) | Ki | 0.2729 | 4 | 4 |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | Ki | 0.7000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3A | Homo sapiens (human) | IC50 | 0.0060 | 2 | 2 |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | IC50 | 16.6980 | 13 | 13 |
| Glutamate receptor ionotropic, NMDA 3A | Homo sapiens (human) | Ki | 0.2729 | 4 | 4 |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | Ki | 0.7000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3B | Homo sapiens (human) | IC50 | 0.0060 | 2 | 2 |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | IC50 | 16.6980 | 13 | 13 |
| Glutamate receptor ionotropic, NMDA 3B | Homo sapiens (human) | Ki | 0.2729 | 4 | 4 |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | Ki | 0.7000 | 1 | 1 |
| Glutathione reductase | Plasmodium falciparum 3D7 | IC50 | 6.4000 | 1 | 1 |
| Glutathione reductase, mitochondrial | Homo sapiens (human) | IC50 | 16.2000 | 2 | 2 |
| High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A | Homo sapiens (human) | IC50 | 200.0000 | 2 | 2 |
| High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A | Homo sapiens (human) | IC50 | 127.6669 | 3 | 13 |
| High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B | Homo sapiens (human) | IC50 | 16.0000 | 1 | 1 |
| High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A | Homo sapiens (human) | IC50 | 16.0000 | 1 | 1 |
| High affinity nerve growth factor receptor | Homo sapiens (human) | IC50 | 60.0000 | 1 | 1 |
| Histamine H1 receptor | Homo sapiens (human) | IC50 | 0.0698 | 4 | 10 |
| Histamine H1 receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0002 | 1 | 14 |
| Histamine H1 receptor | Cavia porcellus (domestic guinea pig) | Ki | 0.0060 | 1 | 1 |
| Histamine H1 receptor | Homo sapiens (human) | Ki | 0.0063 | 8 | 15 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | IC50 | 2.3657 | 1 | 7 |
| Histamine H2 receptor | Homo sapiens (human) | IC50 | 1.5976 | 1 | 5 |
| Histamine H2 receptor | Homo sapiens (human) | Ki | 1.5712 | 1 | 5 |
| Histamine H3 receptor | Homo sapiens (human) | Ki | 3.0000 | 2 | 2 |
| Histamine H3 receptor | Rattus norvegicus (Norway rat) | Ki | 5.0000 | 1 | 1 |
| Histamine H4 receptor | Homo sapiens (human) | Ki | 5.0120 | 1 | 1 |
| Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) | IC50 | 498.7000 | 1 | 1 |
| Inhibitor of nuclear factor kappa-B kinase subunit beta | Homo sapiens (human) | IC50 | 9.8200 | 1 | 1 |
| integrase, partial | Human immunodeficiency virus 1 | IC50 | 19.2405 | 2 | 2 |
| Integrin alpha-5 | Homo sapiens (human) | IC50 | 1.8000 | 1 | 1 |
| Interstitial collagenase | Homo sapiens (human) | IC50 | 50.1200 | 1 | 1 |
| Intestinal-type alkaline phosphatase | Homo sapiens (human) | IC50 | 5.0000 | 1 | 1 |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | IC50 | 250.0000 | 1 | 1 |
| Krueppel-like factor 10 | Homo sapiens (human) | IC50 | 100.0000 | 2 | 2 |
| Large neutral amino acids transporter small subunit 1 | Homo sapiens (human) | IC50 | 160.0000 | 2 | 2 |
| lens epithelium-derived growth factor p75 | Homo sapiens (human) | IC50 | 19.2405 | 2 | 2 |
| Lethal(3)malignant brain tumor-like protein 1 | Homo sapiens (human) | IC50 | 41.0000 | 1 | 1 |
| Lethal(3)malignant brain tumor-like protein 3 | Homo sapiens (human) | IC50 | 42.0000 | 1 | 1 |
| Lethal(3)malignant brain tumor-like protein 4 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Lysine-specific histone demethylase 1A | Homo sapiens (human) | IC50 | 0.1100 | 2 | 2 |
| MBT domain-containing protein 1 | Homo sapiens (human) | IC50 | 34.0000 | 1 | 1 |
| Melanocortin receptor 5 | Homo sapiens (human) | IC50 | 4.5980 | 1 | 1 |
| Melanocortin receptor 5 | Homo sapiens (human) | Ki | 4.3132 | 1 | 1 |
| Microtubule-associated protein tau | Homo sapiens (human) | IC50 | 9.4250 | 4 | 4 |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | IC50 | 0.0003 | 1 | 1 |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | Ki | 0.0400 | 1 | 1 |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | Ki | 1.2000 | 1 | 1 |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 | 125.7250 | 1 | 20 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | IC50 | 0.5386 | 1 | 8 |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | IC50 | 0.3000 | 1 | 4 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | Ki | 2.0042 | 2 | 9 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | IC50 | 0.9909 | 1 | 8 |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | IC50 | 0.3000 | 1 | 3 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | Ki | 0.3524 | 1 | 8 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | IC50 | 0.5430 | 1 | 7 |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | IC50 | 0.3000 | 1 | 3 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | Ki | 0.1152 | 1 | 7 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | IC50 | 0.8639 | 1 | 8 |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | IC50 | 0.3000 | 1 | 3 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | Ki | 0.1204 | 1 | 8 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | IC50 | 0.2400 | 1 | 8 |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | IC50 | 0.6200 | 2 | 5 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | Ki | 0.1727 | 1 | 8 |
| Myeloperoxidase | Homo sapiens (human) | IC50 | 3.3167 | 2 | 3 |
| Neuromedin-K receptor | Homo sapiens (human) | Ki | 0.4541 | 1 | 1 |
| Neuronal acetylcholine receptor subunit alpha-3 | Homo sapiens (human) | IC50 | 1.3670 | 6 | 6 |
| Neuronal acetylcholine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | IC50 | 6.0000 | 1 | 1 |
| Neuronal acetylcholine receptor subunit alpha-4 | Homo sapiens (human) | IC50 | 9.0039 | 7 | 7 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Ki | 3.0000 | 1 | 1 |
| Neuronal acetylcholine receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | IC50 | 6.0000 | 1 | 1 |
| Neuronal acetylcholine receptor subunit alpha-7 | Homo sapiens (human) | IC50 | 28.9500 | 2 | 2 |
| Neuronal acetylcholine receptor subunit beta-2 | Homo sapiens (human) | IC50 | 6.4687 | 6 | 6 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Ki | 3.0000 | 1 | 1 |
| Neuronal acetylcholine receptor subunit beta-4 | Homo sapiens (human) | IC50 | 4.2771 | 8 | 8 |
| Neuronal acetylcholine receptor subunit beta-4 | Rattus norvegicus (Norway rat) | IC50 | 6.0000 | 1 | 1 |
| neutrophil cytosol factor 1 | Homo sapiens (human) | IC50 | 0.3900 | 1 | 1 |
| Nociceptin receptor | Homo sapiens (human) | IC50 | 5.0000 | 1 | 1 |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | IC50 | 16.0464 | 1 | 4 |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | Ki | 13.1465 | 1 | 4 |
| Oxoeicosanoid receptor 1 | Homo sapiens (human) | IC50 | 2.0000 | 1 | 1 |
| P2X purinoceptor 4 | Homo sapiens (human) | IC50 | 2.8067 | 3 | 3 |
| P2X purinoceptor 4 | Rattus norvegicus (Norway rat) | IC50 | 2.4500 | 2 | 2 |
| P2Y purinoceptor 12 | Homo sapiens (human) | Ki | 36.4000 | 1 | 1 |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Peroxisome proliferator-activated receptor alpha | Mus musculus (house mouse) | IC50 | 1.1500 | 1 | 1 |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | IC50 | 5.4081 | 8 | 8 |
| Peroxisome proliferator-activated receptor gamma | Mus musculus (house mouse) | IC50 | 0.7000 | 1 | 1 |
| Peroxisome proliferator-activated receptor gamma | Rattus norvegicus (Norway rat) | IC50 | 0.7000 | 1 | 1 |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | Ki | 0.5761 | 8 | 8 |
| Phosphodiesterase | Rattus norvegicus (Norway rat) | IC50 | 100.0000 | 1 | 1 |
| Phosphodiesterase | Sus scrofa (pig) | IC50 | 100.0000 | 1 | 1 |
| Phosphodiesterase | Trypanosoma brucei | IC50 | 100.0000 | 1 | 1 |
| Phospholipase A-2-activating protein | Homo sapiens (human) | IC50 | 5.0000 | 1 | 1 |
| Pleiotropic ABC efflux transporter of multiple drugs | Saccharomyces cerevisiae S288C | IC50 | 211.0000 | 1 | 2 |
| Polyphenol oxidase 2 | Agaricus bisporus | IC50 | 400.0000 | 1 | 1 |
| Potassium voltage-gated channel subfamily A member 3 | Homo sapiens (human) | IC50 | 31.9000 | 1 | 1 |
| Potassium voltage-gated channel subfamily D member 3 | Homo sapiens (human) | IC50 | 5,011.8700 | 1 | 1 |
| Potassium voltage-gated channel subfamily E member 1 | Homo sapiens (human) | IC50 | 158.4890 | 1 | 1 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 | 452.2737 | 30 | 48 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | Ki | 13.1465 | 1 | 4 |
| Potassium voltage-gated channel subfamily KQT member 1 | Homo sapiens (human) | IC50 | 158.4890 | 1 | 1 |
| Prolyl endopeptidase | Sus scrofa (pig) | IC50 | 0.0060 | 1 | 1 |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | IC50 | 5.1333 | 2 | 3 |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | Ki | 0.1600 | 1 | 2 |
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | IC50 | 13.0000 | 1 | 1 |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | IC50 | 7.1000 | 1 | 1 |
| Protein cereblon | Homo sapiens (human) | IC50 | 202.0000 | 1 | 1 |
| Protein cereblon | Homo sapiens (human) | Ki | 102.0000 | 1 | 1 |
| Protein kinase C alpha type | Homo sapiens (human) | IC50 | 160.0000 | 2 | 2 |
| Protein kinase C beta type | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Protein kinase C delta type | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Protein kinase C epsilon type | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Protein kinase C eta type | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Protein kinase C gamma type | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Protein kinase C iota type | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Protein kinase C theta type | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Protein kinase C zeta type | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Quinolone resistance protein NorA | Staphylococcus aureus | IC50 | 7.0000 | 1 | 1 |
| Renin | Homo sapiens (human) | IC50 | 3.5000 | 1 | 3 |
| Retina-specific copper amine oxidase | Homo sapiens (human) | IC50 | 0.0003 | 1 | 1 |
| Retinoic acid receptor RXR-alpha | Homo sapiens (human) | Ki | 7.6320 | 1 | 1 |
| Rhodopsin kinase GRK1 | Bos taurus (cattle) | IC50 | 243.1750 | 4 | 4 |
| Rhodopsin kinase GRK1 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Serine/threonine-protein kinase D1 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Serine/threonine-protein kinase D3 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Serine/threonine-protein kinase PLK1 | Homo sapiens (human) | IC50 | 2.1800 | 1 | 1 |
| Serine/threonine-protein kinase PLK2 | Homo sapiens (human) | IC50 | 14.7200 | 1 | 1 |
| Serine/threonine-protein kinase PLK3 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| Sex hormone-binding globulin | Homo sapiens (human) | IC50 | 230.0000 | 1 | 1 |
| Sigma intracellular receptor 2 | Rattus norvegicus (Norway rat) | IC50 | 1,000.0000 | 1 | 1 |
| Sigma intracellular receptor 2 | Homo sapiens (human) | Ki | 0.2000 | 1 | 1 |
| Sigma intracellular receptor 2 | Mus musculus (house mouse) | Ki | 0.5050 | 1 | 1 |
| Sigma intracellular receptor 2 | Rattus norvegicus (Norway rat) | Ki | 5.2810 | 1 | 3 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | IC50 | 1.7771 | 1 | 6 |
| Sigma non-opioid intracellular receptor 1 | Rattus norvegicus (Norway rat) | IC50 | 10.0000 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | Ki | 0.5193 | 3 | 9 |
| Sigma non-opioid intracellular receptor 1 | Mus musculus (house mouse) | Ki | 0.0029 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | Rattus norvegicus (Norway rat) | Ki | 0.1180 | 2 | 4 |
| Sodium channel protein type 1 subunit alpha | Homo sapiens (human) | IC50 | 11.8000 | 2 | 2 |
| Sodium channel protein type 1 subunit alpha | Rattus norvegicus (Norway rat) | IC50 | 82.6333 | 2 | 3 |
| Sodium channel protein type 10 subunit alpha | Homo sapiens (human) | IC50 | 54.4000 | 4 | 4 |
| Sodium channel protein type 11 subunit alpha | Homo sapiens (human) | IC50 | 11.8000 | 2 | 2 |
| Sodium channel protein type 2 subunit alpha | Homo sapiens (human) | IC50 | 25.6167 | 6 | 6 |
| Sodium channel protein type 2 subunit alpha | Rattus norvegicus (Norway rat) | IC50 | 63.5800 | 4 | 5 |
| Sodium channel protein type 3 subunit alpha | Homo sapiens (human) | IC50 | 13.5333 | 3 | 3 |
| Sodium channel protein type 3 subunit alpha | Rattus norvegicus (Norway rat) | IC50 | 82.6333 | 2 | 3 |
| Sodium channel protein type 4 subunit alpha | Homo sapiens (human) | IC50 | 11.8000 | 2 | 2 |
| Sodium channel protein type 4 subunit alpha | Homo sapiens (human) | Ki | 17.0000 | 1 | 1 |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | IC50 | 78.3685 | 10 | 10 |
| Sodium channel protein type 7 subunit alpha | Homo sapiens (human) | IC50 | 11.8000 | 2 | 2 |
| Sodium channel protein type 8 subunit alpha | Homo sapiens (human) | IC50 | 11.8000 | 2 | 2 |
| Sodium channel protein type 9 subunit alpha | Homo sapiens (human) | IC50 | 9.7200 | 5 | 5 |
| Sodium- and chloride-dependent betaine transporter | Mus musculus (house mouse) | IC50 | 170.4120 | 1 | 2 |
| Sodium- and chloride-dependent betaine transporter | Rattus norvegicus (Norway rat) | IC50 | 0.0910 | 1 | 1 |
| Sodium- and chloride-dependent GABA transporter 1 | Mus musculus (house mouse) | IC50 | 389.0225 | 1 | 2 |
| Sodium- and chloride-dependent GABA transporter 1 | Rattus norvegicus (Norway rat) | IC50 | 0.0910 | 1 | 1 |
| Sodium- and chloride-dependent GABA transporter 2 | Mus musculus (house mouse) | IC50 | 269.5765 | 1 | 2 |
| Sodium- and chloride-dependent GABA transporter 2 | Rattus norvegicus (Norway rat) | IC50 | 0.0910 | 1 | 1 |
| Sodium- and chloride-dependent GABA transporter 3 | Mus musculus (house mouse) | IC50 | 250.0945 | 1 | 2 |
| Sodium- and chloride-dependent GABA transporter 3 | Rattus norvegicus (Norway rat) | IC50 | 0.0910 | 1 | 1 |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | IC50 | 1.4578 | 6 | 20 |
| Sodium-dependent dopamine transporter | Mus musculus (house mouse) | Ki | 5.2300 | 1 | 2 |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | Ki | 2.5884 | 4 | 6 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | IC50 | 7.6032 | 37 | 46 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | Ki | 1.1488 | 10 | 24 |
| Sodium-dependent noradrenaline transporter | Mus musculus (house mouse) | Ki | 0.0160 | 2 | 3 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | IC50 | 0.5809 | 59 | 84 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | Ki | 0.3623 | 29 | 43 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | IC50 | 3.5513 | 53 | 74 |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | IC50 | 1.3381 | 14 | 20 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | Ki | 0.3483 | 47 | 63 |
| Sodium-dependent serotonin transporter | Mus musculus (house mouse) | Ki | 0.0158 | 2 | 3 |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | Ki | 0.0564 | 8 | 13 |
| Solute carrier family 22 member 1 | Rattus norvegicus (Norway rat) | IC50 | 15.8333 | 2 | 3 |
| Solute carrier family 22 member 1 | Rattus norvegicus (Norway rat) | Ki | 2.8000 | 1 | 1 |
| Solute carrier family 22 member 1 | Homo sapiens (human) | IC50 | 23.0320 | 3 | 10 |
| Solute carrier family 22 member 1 | Homo sapiens (human) | Ki | 5.3600 | 1 | 1 |
| Solute carrier family 22 member 2 | Homo sapiens (human) | IC50 | 0.6000 | 1 | 1 |
| Solute carrier family 22 member 2 | Rattus norvegicus (Norway rat) | IC50 | 15.3000 | 2 | 3 |
| Solute carrier family 22 member 2 | Homo sapiens (human) | Ki | 16.0000 | 1 | 1 |
| Solute carrier family 22 member 3 | Rattus norvegicus (Norway rat) | IC50 | 68.0000 | 1 | 1 |
| Solute carrier family 22 member 3 | Homo sapiens (human) | Ki | 28.0000 | 1 | 2 |
| Solute carrier family 22 member 4 | Rattus norvegicus (Norway rat) | IC50 | 80.0000 | 1 | 1 |
| Sphingomyelin phosphodiesterase | Homo sapiens (human) | IC50 | 5.0000 | 1 | 1 |
| Steryl-sulfatase | Homo sapiens (human) | IC50 | 0.8000 | 1 | 1 |
| Stromelysin-1 | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| Substance-P receptor | Cavia porcellus (domestic guinea pig) | IC50 | 500.0000 | 1 | 3 |
| Substance-P receptor | Homo sapiens (human) | IC50 | 0.0820 | 11 | 11 |
| Substance-P receptor | Meriones unguiculatus (Mongolian gerbil) | IC50 | 0.0001 | 1 | 1 |
| Substance-P receptor | Homo sapiens (human) | Ki | 0.0013 | 3 | 3 |
| Sulfotransferase 1A1 | Homo sapiens (human) | Ki | 70.3333 | 1 | 6 |
| Sulfotransferase 2A1 | Homo sapiens (human) | Ki | 70.3333 | 1 | 6 |
| Telomerase reverse transcriptase | Homo sapiens (human) | IC50 | 36.0000 | 1 | 1 |
| Thioredoxin reductase 1, cytoplasmic | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| Tissue factor | Homo sapiens (human) | IC50 | 78.0000 | 1 | 1 |
| TPA: protein transporter TIM10 | Saccharomyces cerevisiae S288C | IC50 | 37.8000 | 1 | 1 |
| Transcriptional activator protein LuxR | Aliivibrio fischeri | IC50 | 27.0000 | 1 | 1 |
| Transporter | Rattus norvegicus (Norway rat) | IC50 | 2.1216 | 7 | 12 |
| Transporter | Rattus norvegicus (Norway rat) | Ki | 0.1192 | 7 | 13 |
| Trypanothione reductase | Trypanosoma brucei brucei | IC50 | 3.4000 | 1 | 1 |
| Trypanothione reductase | Trypanosoma cruzi | IC50 | 13.7500 | 2 | 2 |
| Trypanothione reductase | Trypanosoma cruzi | Ki | 6.6250 | 4 | 4 |
| Trypsin | Sus scrofa (pig) | IC50 | 200.0000 | 1 | 1 |
| Tryptophan 2,3-dioxygenase | Homo sapiens (human) | Ki | 11,500.0000 | 1 | 1 |
| Tryptophan 5-hydroxylase 1 | Rattus norvegicus (Norway rat) | Ki | 0.0106 | 1 | 3 |
| Tumor necrosis factor | Homo sapiens (human) | IC50 | 4.2333 | 3 | 3 |
| Type-1 angiotensin II receptor | Bos taurus (cattle) | IC50 | 0.1800 | 1 | 1 |
| Type-1 angiotensin II receptor | Oryctolagus cuniculus (rabbit) | IC50 | 47.3000 | 1 | 1 |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | IC50 | 0.2100 | 1 | 1 |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | Ki | 0.5000 | 1 | 1 |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | IC50 | 220.0000 | 1 | 1 |
| ubiquitin-conjugating enzyme E2 N | Homo sapiens (human) | IC50 | 20.0000 | 1 | 3 |
| UDP-glucuronosyltransferase 1-6 | Homo sapiens (human) | IC50 | 228.0000 | 1 | 5 |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | IC50 | 228.0000 | 1 | 5 |
| UDP-glucuronosyltransferase 1A4 | Homo sapiens (human) | IC50 | 228.0000 | 1 | 5 |
| UDP-glucuronosyltransferase 2B10 | Homo sapiens (human) | IC50 | 228.0000 | 1 | 5 |
| UDP-glucuronosyltransferase 2B7 | Homo sapiens (human) | IC50 | 228.0000 | 1 | 5 |
| Uracil nucleotide/cysteinyl leukotriene receptor | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Cavia porcellus (domestic guinea pig) | IC50 | 8.3000 | 1 | 2 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | IC50 | 573.5240 | 5 | 5 |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | IC50 | 7.9333 | 3 | 3 |
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | IC50 | 7.9333 | 3 | 3 |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | IC50 | 7.9333 | 3 | 3 |
| Voltage-dependent N-type calcium channel subunit alpha-1B | Homo sapiens (human) | IC50 | 14.0000 | 1 | 9 |
| Xanthine dehydrogenase/oxidase | Homo sapiens (human) | IC50 | 213.0000 | 1 | 1 |